查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1577408

亨廷頓舞蹈症藥物市場：按類型、最終用戶分類 - 全球預測 2025-2030

Huntington's Disease Therapeutics Market by Type (Disease-modifying Therapies, Gene Therapies, Medication), End-User (Hospitals, Long-Term Care Facilities, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年亨廷頓病治療市值為5.1601億美元，預計到2024年將達到5.9743億美元，複合年成長率為17.14%，預計到2030年將達到15.6174億美元。

亨丁頓舞蹈症藥物包括多種旨在控制症狀或減緩亨丁頓舞蹈症進展的治療方法，亨丁頓舞蹈症是一種以腦神經細胞進行性退化為特徵的遺傳性疾病。需要這些藥物是因為亨廷頓舞蹈症對患者的生活品質有重大影響，對家庭和醫療保健系統帶來身體和經濟負擔，而且目前還沒有既定的治療方法。應用包括藥物治療、基因靜默方法以及臨床試驗中的先進治療，例如 CRISPR 和RNA干擾技術，這些技術已顯示出改變疾病遺傳軌跡的潛力。最終用途範圍已顯著擴展到醫院、專科診所和專注於神經退化性疾病的研究機構。

主要市場統計
基準年[2023] 51601萬美元
預測年份 [2024] 5.9743 億美元
預測年份 [2030] 15.6174億美元
複合年成長率（%） 17.14%

市場成長受到研發資金增加、遺傳和基因組科學進步以及創新候選藥物不斷增加的影響。最近的商機在於個人化醫療方法和跨產業合作，以加速新型療法的開發和商業化。然而，它也存在局限性，包括複雜的監管環境、高昂的開發成本以及針對中樞神經系統的有效藥物的固有挑戰。由於這種疾病的罕見性和基因檢測的倫理考慮，招募患者進行臨床試驗仍然很困難。

創新和研究的最佳領域包括改進更有效地穿過血腦障壁的藥物輸送系統、開發更精確的基因編輯工具以及增強用於早期診斷的生物標記。與科技公司合作利用人工智慧進行深度表現型分析和藥物發現具有巨大的潛力。市場仍然充滿活力，重點是轉化研究和跨學科方法的整合。相關人員應強調強力的夥伴關係和以患者為中心的模式，以克服現有挑戰並利用快速發展的亨廷頓病藥物領域的新機會。

市場動態：揭示快速發展的亨廷頓病藥物市場的關鍵市場洞察

供應和需求的動態交互作用正在改變亨廷頓氏症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對抑制亨丁頓舞蹈症症狀的藥物的需求不斷增加
    • 政府不斷採取措施提高人們對亨丁頓舞蹈症的認知
  • 市場限制因素
    • 先進治療相關的高成本
  • 市場機會
    • 增加臨床研究活動以開發亨廷頓舞蹈症療法
    • 亨丁頓舞蹈症患者的藥物核准增加
  • 市場挑戰
    • 亨廷頓舞蹈症療法開發中與嚴格監管政策相關的問題

波特五力：駕馭亨丁頓舞蹈症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對亨丁頓舞蹈症藥物市場的影響

外部宏觀環境因素在塑造亨廷頓舞蹈症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解亨丁頓舞蹈症治療藥物市場的競爭狀況

對亨廷頓舞蹈症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣亨丁頓舞蹈症治療市場供應商的績效評估

FPNV 定位矩陣是評估亨丁頓舞蹈症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為亨丁頓舞蹈症藥物市場的成功指明道路

對於希望加強在全球市場的影響力的公司來說，亨廷頓舞蹈症治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對抑制亨丁頓舞蹈症症狀的藥物的需求增加
      • 政府加強提高人們對亨丁頓舞蹈症的認知
    • 抑制因素
      • 與先進治療相關的高成本
    • 機會
      • 擴大臨床研究活動以開發亨廷頓氏舞蹈症的治療藥物
      • 亨丁頓舞蹈症患者的藥物核准增加
    • 任務
      • 亨丁頓舞蹈症藥物開發的嚴格監管政策相關議題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章亨廷頓氏症治療藥物市場：依類型

  • 疾病修正治療
  • 基因治療
  • 藥物治療
  • 職能治療
  • 治療

第7章亨廷頓氏症治療藥物市場：依最終使用者分類

  • 醫院
  • 長期照護設施
  • 專科診所

第8章 美洲亨廷頓病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區亨廷頓氏症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲亨廷頓舞蹈症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-69324464D29B

The Huntington's Disease Therapeutics Market was valued at USD 516.01 million in 2023, expected to reach USD 597.43 million in 2024, and is projected to grow at a CAGR of 17.14%, to USD 1,561.74 million by 2030.

Huntington's Disease Therapeutics encompass a range of treatments aimed at managing the symptoms or slowing the progression of Huntington's Disease, a genetic disorder characterized by the progressive degeneration of nerve cells in the brain. The necessity for these therapeutics arises from the absence of a cure for Huntington's, alongside the significant impact the disorder has on patients' quality of life and the physical and economic burden it imposes on families and healthcare systems. The application includes pharmacological treatments, gene-silencing approaches, and advanced therapies in clinical trials, such as CRISPR and RNA interference technologies, which showcase potential in altering the genetic trajectory of the disease. The end-use scope largely spans hospitals, specialty clinics, and research institutions focused on neurodegenerative disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 516.01 million
Estimated Year [2024] USD 597.43 million
Forecast Year [2030] USD 1,561.74 million
CAGR (%) 17.14%

Market growth is influenced by increasing funding for research and development, advances in genetic and genomic sciences, and a growing pipeline of innovative drug candidates. Recent opportunities lie in personalized medicine approaches and cross-industry partnerships to expedite novel therapeutics' development and distribution. However, limitations include the complex regulatory landscape, high costs of development, and the inherent challenges of targeting the central nervous system with effective drugs. Patient recruitment for clinical trials remains challenging due to the disease's rarity and ethical considerations surrounding genetic testing.

The best areas for innovation and research include improving drug delivery systems to cross the blood-brain barrier efficiently, developing more precise gene-editing tools, and enhancing biomarkers for early diagnosis. Collaboration with technology firms to leverage AI for deep phenotyping and drug discovery offers substantial potential. The market remains dynamic, with a strong emphasis on translational research and the integration of multidisciplinary approaches. Stakeholders should focus on robust partnerships and patient-centric models to overcome existing challenges and capitalize on emerging opportunities in the rapidly advancing landscape of Huntington's Disease therapeutics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Huntington's Disease Therapeutics Market

The Huntington's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in need for drugs to control Huntington's disease symptoms
    • Rising government initiatives to increase awareness about Huntington's disease
  • Market Restraints
    • High cost associated with advanced treatments
  • Market Opportunities
    • Increase in clinical research activities for drug development for Huntington's disease
    • Growing drug approvals for the treatment of Huntington's disease patients
  • Market Challenges
    • Problems associated with strict regulatory policies for development of Huntington's disease drugs

Porter's Five Forces: A Strategic Tool for Navigating the Huntington's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Huntington's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Huntington's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Huntington's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Huntington's Disease Therapeutics Market

A detailed market share analysis in the Huntington's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Huntington's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Huntington's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Huntington's Disease Therapeutics Market

A strategic analysis of the Huntington's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Huntington's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Alterity Therapeutics Limited, Annexon Biosciences, AOP Orphan Pharmaceuticals GmbH, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals Inc., Ipsen S.A., Lupin Limited, Medesis Pharma SA, Mitochon Pharmaceuticals, Inc., NeuExcell Therapeutics Inc, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Prilenia Therapeutics B.V., PTC Therapeutics Inc., SOM Innovation Biotech S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., uniQure N.V., Vaccinex Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Huntington's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Disease-modifying Therapies, Gene Therapies, Medication, Occupational Therapies, and Symptomatic Treatment.
  • Based on End-User, market is studied across Hospitals, Long-Term Care Facilities, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in need for drugs to control Huntington's disease symptoms
      • 5.1.1.2. Rising government initiatives to increase awareness about Huntington's disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in clinical research activities for drug development for Huntington's disease
      • 5.1.3.2. Growing drug approvals for the treatment of Huntington's disease patients
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with strict regulatory policies for development of Huntington's disease drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Huntington's Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Disease-modifying Therapies
  • 6.3. Gene Therapies
  • 6.4. Medication
  • 6.5. Occupational Therapies
  • 6.6. Symptomatic Treatment

7. Huntington's Disease Therapeutics Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Long-Term Care Facilities
  • 7.4. Specialty Clinics

8. Americas Huntington's Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Huntington's Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Huntington's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Alterity Therapeutics Limited
  • 3. Annexon Biosciences
  • 4. AOP Orphan Pharmaceuticals GmbH
  • 5. Bausch Health Companies Inc.
  • 6. Dr. Reddy's Laboratories Ltd.
  • 7. Hikma Pharmaceuticals PLC
  • 8. Ionis Pharmaceuticals Inc.
  • 9. Ipsen S.A.
  • 10. Lupin Limited
  • 11. Medesis Pharma SA
  • 12. Mitochon Pharmaceuticals, Inc.
  • 13. NeuExcell Therapeutics Inc
  • 14. Neurocrine Biosciences, Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Prilenia Therapeutics B.V.
  • 18. PTC Therapeutics Inc.
  • 19. SOM Innovation Biotech S.A.
  • 20. Sun Pharmaceutical Industries Limited
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. uniQure N.V.
  • 23. Vaccinex Inc.
  • 24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. HUNTINGTON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HUNTINGTON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUNTINGTON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY OCCUPATIONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. HUNTINGTON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023